Vulvovaginal candidiasis is the second most common cause of infectious vaginitis, affecting an estimated 75% of women at least once before menopause and accounting for ~1.4 million annual outpatient visits in the United States. [1-2] Candida albicans is the causative organism in ~90% of cases; non-albicans species (especially C. glabrata) are increasingly recognized. [3-4]
The following diagnostic algorithm from the AAFP provides a practical framework for evaluating vaginitis presentations:
1. History
- Chief complaint: Vulvovaginal itching, burning, irritation, soreness, external dysuria, dyspareunia [3]
- Discharge character: White, thick, "cottage cheese" or curd-like; typically odorless [5]
- Timing/triggers: Onset relative to menses (often premenstrual flare), recent antibiotic use, new sexual partner, hormonal changes (OCP initiation, pregnancy)
- Severity: Mild intermittent pruritus vs. severe edema/fissuring (suggests complicated VVC)
- Recurrence: ≥4 episodes in 12 months defines recurrent VVC (RVVC) — ask about prior episodes, prior treatments, and response to therapy [3]
- Important negatives: Absence of malodor (argues against BV), absence of frothy discharge (argues against trichomoniasis), no fever or pelvic pain (argues against PID) [5-6]
2. Alarm Features
- Fever, cervical motion tenderness, adnexal mass → consider PID, tubo-ovarian abscess, ectopic pregnancy [5]
- Severe vulvar edema, ulceration, or fissuring → suggests complicated VVC or alternative diagnosis (herpes, Behçet's, vulvar dermatosis) [3]
- Immunocompromised state (HIV with low CD4, uncontrolled diabetes, chronic corticosteroid use) → higher risk for complicated/refractory disease [7-8]
- Failure to respond to appropriate antifungal therapy → consider non-albicans species, azole resistance, or misdiagnosis [6]
3. Medications
- Common treatments — Uncomplicated VVC: [2-3]
- Fluconazole 150 mg PO × 1 dose (preferred by most patients)
- Topical azoles: clotrimazole, miconazole, terconazole (OTC or Rx; 1–7 day courses)
- Clinical cure rates >90% with either oral or topical azoles
- Severe acute VVC: Fluconazole 150 mg PO every 72 hours × 2–3 doses [3]
- Recurrent VVC: Induction (10–14 days topical or oral fluconazole), then fluconazole 150 mg weekly × 6 months [3]
- Newer agents: Oteseconazole (FDA-approved 2022 for RVVC in non-reproductive-potential females); ibrexafungerp (FDA-approved for acute and recurrent VVC) [7-9]
- Non-albicans (C. glabrata): Intravaginal boric acid 600 mg daily × 14 days; nystatin suppositories 100,000 units daily × 14 days [3]
- Medication contributors to VVC: Recent antibiotics (especially broad-spectrum), systemic corticosteroids, high-dose estrogen OCPs [4]
- Contraindications/cautions:
- Fluconazole in pregnancy — associated with spontaneous abortion and craniofacial/cardiac defects; use topical azoles only [8]
- Oteseconazole — contraindicated in women of reproductive potential [9]
- Ibrexafungerp — teratogenic; requires effective contraception during and 4 days after treatment [7]
4. Diet
- No strong evidence supports specific dietary interventions for VVC [8]
- Poorly controlled diabetes is a recognized risk factor — glycemic optimization may reduce recurrence [4]
- Probiotics — no evidence supports their use for treatment or prevention of VVC [8]
- General advice: adequate hydration, avoidance of excessive refined sugars in diabetic patients
5. Review of Systems
- GU: Dysuria (external vs. internal — external suggests vulvitis), vaginal discharge character, dyspareunia, vaginal odor
- GYN: Menstrual cycle timing, pregnancy status, contraceptive use, last Pap smear
- Endocrine: Polyuria/polydipsia (undiagnosed diabetes), weight changes
- Immune: HIV risk factors, immunosuppressive medications, recurrent infections
- Dermatologic: Vulvar skin changes, rashes elsewhere (psoriasis, lichen sclerosus)
- GI: Abdominal/pelvic pain (to rule out PID or other pathology)
6. Collateral History and Family History
- Prior episodes and treatments used (OTC vs. prescription, response)
- Sexual history: new partners, partner symptoms (balanitis)
- Vaginal hygiene practices: douching, scented products (can alter vaginal flora) [6]
- Family history of diabetes or autoimmune conditions
- HIV status and CD4 count if applicable [7]
7. Risk Factors
- Recent antibiotic use (most common modifiable risk factor) [4]
- Hormonal factors: Pregnancy, high-estrogen OCPs, hormone replacement therapy [4]
- Uncontrolled diabetes mellitus [3-4]
- Immunosuppression: HIV (especially CD4 <200), corticosteroids, chemotherapy [7]
- Genetic predisposition — emerging evidence for host immune/genetic factors in RVVC [4]
- Vaginal microbiome disruption — douching, intravaginal products [6]
- Obesity and increased moisture/occlusion in the vulvar area
8. Differential Diagnosis
- Bacterial vaginosis — thin, homogenous discharge; fishy odor; pH >4.5; clue cells on wet mount [5][10]
- Trichomoniasis — frothy green/yellow discharge; strawberry cervix; motile trichomonads; pH >4.5 [5][10]
- Contact/irritant dermatitis — exposure to soaps, detergents, spermicides; no infectious organisms on testing [2][11]
- Atrophic vaginitis — postmenopausal; thin, dry mucosa; pale epithelium [11]
- Desquamative inflammatory vaginitis — purulent discharge, diffuse erythema, parabasal cells on wet mount [11]
- Herpes simplex vulvitis — vesicles/ulcers, pain predominant over itch
- Lichen sclerosus / lichen planus — chronic vulvar changes, architectural distortion
- Cervicitis (chlamydia, gonorrhea) — mucopurulent cervical discharge, WBCs without yeast or trichomonads [6]
9. Past Medical History
- Prior VVC episodes and frequency (classify as uncomplicated vs. recurrent)
- Diabetes mellitus (type and control)
- HIV/immunocompromised status
- Pregnancy history
- Prior gynecologic surgeries
- Chronic skin conditions (eczema, psoriasis — may mimic or coexist)
- Medication history including recent antibiotics, steroids, immunosuppressants
10. Physical Exam
- Vitals: Fever suggests alternative/concurrent diagnosis (PID)
- External genitalia: Vulvar erythema, edema, excoriations, fissures, satellite lesions [3]
- Speculum exam: White, thick, curd-like discharge adherent to vaginal walls; erythematous vaginal mucosa [3][5]
- Bimanual exam: Should be non-tender; cervical motion tenderness or adnexal tenderness → consider PID [5]
- Assess for: Ulcers (HSV), vesicles, vulvar skin changes (lichen sclerosus/planus), frothy discharge (trichomoniasis)
11. Lab Studies
- Vaginal pH: Typically normal (4.0–4.5) in VVC; elevated pH suggests BV or trichomoniasis [3][6]
- Wet mount with saline and 10% KOH: Visualization of pseudohyphae or budding yeast on KOH prep is diagnostic [3][6]
- Vaginal yeast culture: Gold standard, especially for recurrent or treatment-refractory cases — allows species identification [2][8]
- NAAT/PCR panels: Multiplex vaginal panels (BV/VVC/TV) increasingly available; high sensitivity and specificity [8][12]
- Whiff test: Negative in VVC (positive = fishy odor → BV)
- Consider: Glucose/HbA1c if recurrent VVC and diabetes not yet evaluated; HIV testing if risk factors present [7]
12. Imaging
- Not indicated for uncomplicated VVC
- Pelvic ultrasound only if concern for tubo-ovarian abscess, ectopic pregnancy, or adnexal pathology based on exam findings
13. Special Tests
- Point-of-care microscopy (saline wet mount + KOH prep) — sensitivity ~50% compared to culture; specificity is high when positive [6][12]
- Vaginal culture — recommended for recurrent VVC, treatment failure, or suspected non-albicans species [2][8]
- Antifungal susceptibility testing — indicated for patients with persistent positive cultures despite maintenance therapy [6]
- Multiplex NAAT panels — useful when microscopy is unavailable or inconclusive [12]
14. ECG
- Not applicable for VVC
- No ECG indications unless concurrent systemic illness warrants evaluation
15. Assessment
Classification is key to management: [3]
- Uncomplicated VVC (~90% of cases): Sporadic/infrequent, mild-to-moderate symptoms, likely C. albicans, immunocompetent host
- Complicated VVC (~10%): Severe symptoms, recurrent (≥4 episodes/year), non-albicans species, or immunocompromised/diabetic/pregnant patient
Typical presentation: premenstrual pruritus with thick white discharge and vulvar erythema in a reproductive-age woman, often following antibiotic use. Atypical presentations (minimal discharge, predominant dysuria, chronic vulvar irritation) should prompt broader differential evaluation. [3][11]
16. Treatment Plan
Uncomplicated VVC: [2-3]
- Fluconazole 150 mg PO × 1 (most convenient; >90% cure rate)
- OR topical azole (clotrimazole 1% cream × 7 days, miconazole 200 mg suppository × 3 days, etc.)
- Oral and topical routes are equally effective [1][13]
Severe Acute VVC: [3]
Recurrent VVC: [2-3]
- Induction: 10–14 days of topical azole or fluconazole 150 mg PO on days 1, 4, and 7
- Maintenance: Fluconazole 150 mg PO weekly × 6 months (controls >90% of episodes; ~40–50% recurrence after cessation)
- Alternatives: Oteseconazole or ibrexafungerp for eligible patients [7][9]
The following Kaplan-Meier analysis from the landmark Sobel et al. NEJM trial demonstrates the efficacy of weekly fluconazole maintenance in preventing recurrence during the 6-month treatment phase, with subsequent relapse after discontinuation:
Non-albicans VVC (C. glabrata): [3]
- Intravaginal boric acid 600 mg daily × 14 days
- Nystatin suppositories 100,000 units daily × 14 days
- Topical flucytosine 17% cream ± amphotericin B 3% cream × 14 days
Pregnancy: Topical azoles only (7-day course preferred); avoid oral fluconazole [8]
17. Disposition
- Discharge home: The vast majority of VVC cases — uncomplicated VVC is managed entirely outpatient [1-2]
- Observation/admission: Not typically required; consider only if systemic illness, concern for PID/TOA, or severe immunocompromise with systemic candidiasis
- Specialist consultation triggers:
- Recurrent VVC unresponsive to maintenance fluconazole [2][6]
- Suspected azole-resistant species
- Complicated VVC in immunocompromised patients
- Diagnostic uncertainty after appropriate workup
18. Follow Up / Return Precautions
- Uncomplicated VVC: Routine follow-up not necessary if symptoms resolve [1]
- Recurrent VVC: Follow-up in 1–2 weeks after induction to confirm clinical/mycologic response; periodic monitoring during 6-month maintenance [2-3]
- Return precautions — advise patients to return if:
- Symptoms do not improve within 3–5 days of treatment
- Symptoms worsen or new symptoms develop (fever, pelvic pain, abnormal bleeding)
- Recurrence within 2 months of treatment
- Patient counseling:
- Avoid douching and scented vulvar products [6]
- Complete full course of prescribed therapy
- OTC antifungals are appropriate only for patients with prior confirmed VVC who recognize recurrent symptoms; self-diagnosis is inaccurate ~50% of the time [6]
- Expected recovery: symptom improvement within 2–3 days, full resolution within 7 days for uncomplicated cases
References
1. Oral vs. Intravaginal Antifungal Treatments for Uncomplicated Vulvovaginal Candidiasis. — Reedy-Cooper A, Ramirez S, Thomas S. American Family Physician. 2022.
2. Oral vs. Intravaginal Antifungal Treatments for Uncomplicated Vulvovaginal Candidiasis. — Reedy-Cooper A, Ramirez S, Thomas S. American Family Physician. 2022.
3. Oral vs. Intravaginal Antifungal Treatments for Uncomplicated Vulvovaginal Candidiasis. — Reedy-Cooper A, Ramirez S, Thomas S. American Family Physician. 2022.
4. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. — Committee on Practice Bulletins—Gynecology Obstetrics and Gynecology. 2020.
5. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. — Committee on Practice Bulletins—Gynecology Obstetrics and Gynecology. 2020.
6. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. — Pappas PG, Kauffman CA, Andes DR, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2016.
7. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. — Pappas PG, Kauffman CA, Andes DR, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2016.
8. State-of-the-Art Review: Managing Vulvovaginal Candidiasis. — Rautemaa-Richardson R, Sobel JD, Stone N, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2026.
9. State-of-the-Art Review: Managing Vulvovaginal Candidiasis. — Rautemaa-Richardson R, Sobel JD, Stone N, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2026.
10. Vaginitis: Diagnosis and Treatment. — Geer K, Klega A. American Family Physician. 2025.
11. Vaginitis: Diagnosis and Treatment. — Geer K, Klega A. American Family Physician. 2025.
12. Sexually Transmitted Infections Treatment Guidelines, 2021. — Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.
13. Sexually Transmitted Infections Treatment Guidelines, 2021. — Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.
14. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
15. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
16. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. — Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2022.
17. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. — Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2022.
18. FDA Orange Book. — FDA Orange Book. 2026.
19. FDA Orange Book. — FDA Orange Book. 2026.
20. Vaginitis: Diagnosis and Treatment. — Paladine HL, Desai UA. American Family Physician. 2018.
21. Vaginitis: Diagnosis and Treatment. — Paladine HL, Desai UA. American Family Physician. 2018.
22. Noncandidal Vaginitis: A Comprehensive Approach to Diagnosis and Management. — Neal CM, Kus LH, Eckert LO, Peipert JF. American Journal of Obstetrics and Gynecology. 2020.
23. Noncandidal Vaginitis: A Comprehensive Approach to Diagnosis and Management. — Neal CM, Kus LH, Eckert LO, Peipert JF. American Journal of Obstetrics and Gynecology. 2020.
24. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
25. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
26. Treatment of Uncomplicated Vulvovaginal Candidiasis: Topical or Oral Drugs? Single-Day or Multiple-Day Therapy? A Network Meta-Analysis of Randomized Trials. — Gardella B, Dominoni M, Cassani C, Francesca Pasquali M, Spinillo A. American Journal of Obstetrics and Gynecology. 2025.
27. Treatment of Uncomplicated Vulvovaginal Candidiasis: Topical or Oral Drugs? Single-Day or Multiple-Day Therapy? A Network Meta-Analysis of Randomized Trials. — Gardella B, Dominoni M, Cassani C, Francesca Pasquali M, Spinillo A. American Journal of Obstetrics and Gynecology. 2025.
28. Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. — Sobel JD, Wiesenfeld HC, Martens M, et al. The New England Journal of Medicine. 2004.
29. Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. — Sobel JD, Wiesenfeld HC, Martens M, et al. The New England Journal of Medicine. 2004.